Insider Transactions in Q4 2021 at Relay Therapeutics, Inc. (RLAY)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2021
|
Sanjiv Patel President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
658
+0.26%
|
$17,108
$26.1 P/Share
|
|
Dec 31
2021
|
Brian Adams Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
658
+2.5%
|
$17,108
$26.1 P/Share
|
|
Dec 27
2021
|
Brian Adams Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
295
-1.17%
|
$9,735
$33.1 P/Share
|
|
Dec 27
2021
|
Donald A Bergstrom President, R&D |
SELL
Open market or private sale
|
Direct |
649
-1.42%
|
$21,417
$33.1 P/Share
|
|
Dec 27
2021
|
Thomas Catinazzo Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
295
-1.93%
|
$9,735
$33.1 P/Share
|
|
Dec 27
2021
|
Andy Porter Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
260
-1.11%
|
$8,580
$33.1 P/Share
|
|
Nov 15
2021
|
Brian Adams Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
6,500
-20.45%
|
$227,500
$35.42 P/Share
|
|
Nov 15
2021
|
Brian Adams Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,500
+16.98%
|
$26,000
$4.12 P/Share
|
|
Nov 15
2021
|
Thomas Catinazzo Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
22,500
-59.55%
|
$787,500
$35.4 P/Share
|
|
Nov 15
2021
|
Thomas Catinazzo Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,500
+37.32%
|
$90,000
$4.12 P/Share
|
|
Oct 15
2021
|
Donald A Bergstrom President, R&D |
SELL
Open market or private sale
|
Direct |
30,000
-39.67%
|
$1,020,000
$34.15 P/Share
|